Key Insights
The global mRNA Vaccines and Therapeutics market is poised for substantial expansion, with an estimated market size of $54.70 million in 2025, driven by a robust CAGR of 16.80%. This remarkable growth trajectory is underpinned by significant advancements in mRNA technology and its expanding applications across critical healthcare areas. The market is segmented by Vaccine Type, with self-amplifying mRNA-based vaccines and conventional non-amplifying mRNA-based vaccines both showing promise, catering to diverse therapeutic needs. Application segments such as cancer, infectious diseases, and autoimmune diseases are witnessing intensified research and development efforts, with mRNA's inherent flexibility enabling the creation of highly targeted and effective treatments. The treatment types, including monoclonal antibody, gene therapy, and cell therapy, are also benefiting from mRNA innovation, offering novel therapeutic modalities. Key end-users like research laboratories, hospitals, and clinics are actively adopting these cutting-edge solutions, further fueling market growth. Leading companies such as Pfizer Inc., Moderna Inc., AstraZeneca, and BioNTech SE are at the forefront, investing heavily in innovation and clinical trials, creating a competitive yet dynamic market landscape.
mRNA Vaccines Therapeutics Market Market Size (In Million)
The market's upward momentum is further propelled by crucial drivers such as the increasing prevalence of chronic and infectious diseases, the growing demand for personalized medicine, and substantial government and private sector investments in vaccine and therapeutic research. The rapid development and deployment of mRNA vaccines during recent global health crises have also significantly boosted confidence and accelerated the adoption of mRNA-based solutions. While the market demonstrates immense potential, certain restraints, including the high cost of development and manufacturing, stringent regulatory hurdles, and the need for enhanced cold-chain infrastructure, need to be strategically addressed. Nevertheless, ongoing technological innovations, such as improved delivery systems and enhanced mRNA stability, coupled with strategic collaborations and partnerships among major players, are expected to overcome these challenges. The Asia Pacific region, in particular, is anticipated to emerge as a significant growth hub, driven by expanding healthcare infrastructure and a burgeoning patient population.
mRNA Vaccines Therapeutics Market Company Market Share
Dive deep into the transformative landscape of mRNA technology with our comprehensive report on the mRNA Vaccines Therapeutics Market. This in-depth analysis, covering the period from 2019 to 2033 with a base and estimated year of 2025, provides critical insights for stakeholders seeking to capitalize on the burgeoning mRNA revolution. Discover market dynamics, key growth drivers, emerging opportunities, and the strategic moves of leading players shaping the future of healthcare. We delve into the intricate details of vaccine types, application areas, treatment modalities, and end-user segments, offering a granular view of this rapidly evolving sector.
mRNA Vaccines Therapeutics Market Market Composition & Trends
The mRNA Vaccines Therapeutics Market is characterized by a dynamic and evolving composition, driven by relentless innovation and significant investment. Market concentration, while present among major players, is also seeing the emergence of agile biotech firms pushing the boundaries of mRNA science. Innovation catalysts are numerous, ranging from advancements in delivery systems and platform technologies to the expansion of therapeutic targets beyond infectious diseases. The regulatory landscape, while robust, is adapting to accommodate the unique nature of mRNA therapeutics, fostering a climate of cautious optimism. Substitute products, primarily traditional vaccines and small molecule drugs, still hold significant market share, but the superior efficacy, speed of development, and versatility of mRNA platforms are increasingly challenging their dominance. End-user profiles are expanding, with a growing demand from research institutions for novel drug development and from healthcare providers for effective preventative and therapeutic solutions. Mergers & Acquisitions (M&A) activities are a significant trend, with substantial deal values reflecting the strategic importance of acquiring mRNA expertise and pipeline assets. Market share distribution is undergoing a rapid shift, with established pharmaceutical giants and innovative biotech companies vying for leadership.
mRNA Vaccines Therapeutics Market Industry Evolution
The mRNA Vaccines Therapeutics Market has witnessed an unprecedented industry evolution, largely catalyzed by the rapid development and deployment of COVID-19 vaccines. This period, from 2019 to the present, has been a watershed moment, accelerating research, development, and regulatory pathways. The initial focus on infectious diseases has paved the way for a broader exploration of mRNA's potential in diverse therapeutic areas. Market growth trajectories have been steep, driven by the overwhelming success of mRNA vaccines against SARS-CoV-2. Technological advancements have been relentless, encompassing improvements in mRNA design, lipid nanoparticle (LNP) delivery systems, and manufacturing scalability. These advancements have not only enhanced vaccine efficacy and safety but also reduced production costs, making mRNA therapeutics more accessible. Shifting consumer demands are increasingly favoring rapid, effective, and personalized medical interventions, a paradigm that mRNA technology is exceptionally well-positioned to fulfill. Adoption metrics for mRNA-based therapies are expected to climb significantly as more applications move through clinical trials and gain regulatory approval. The historical period of 2019-2024 laid the groundwork, with foundational research and early-stage development, while the current forecast period of 2025-2033 is poised for exponential growth and diversification. The estimated market size in 2025 is projected to be in the range of $25,000 Million to $35,000 Million, with an anticipated CAGR of 15% to 20% over the forecast period, reflecting the sustained and robust expansion of this sector.
Leading Regions, Countries, or Segments in mRNA Vaccines Therapeutics Market
The mRNA Vaccines Therapeutics Market is exhibiting significant dominance across several key segments, with a clear focus on certain regions and therapeutic applications. Infectious Diseases currently represent the largest application segment, a trend heavily influenced by the global demand for COVID-19 vaccines and the ongoing need for rapid responses to emerging pandemics. The self-amplifying mRNA-based vaccines segment is gaining traction due to its potential for enhanced immunogenicity and reduced dosing requirements, though conventional non-amplifying mRNA-based vaccines remain a strong contender due to their established track record and widespread adoption. Within treatment types, the development of mRNA for Monoclonal Antibodies and Gene Therapy applications is showing immense promise, offering novel therapeutic avenues for previously untreatable conditions. For end-users, Hospitals and Clinics are the primary recipients of approved mRNA therapeutics, driven by direct patient care and vaccination programs.
Dominant Application: Infectious Diseases
- Key Drivers:
- Ongoing global health security concerns and the need for rapid vaccine development against novel pathogens.
- Established success and infrastructure built around COVID-19 vaccines, facilitating quicker development for other infectious agents.
- High public and governmental investment in pandemic preparedness.
- The potential for broad-spectrum antiviral vaccines.
- Key Drivers:
Promising Treatment Type: Gene Therapy
- Key Drivers:
- The inherent ability of mRNA to instruct cells to produce therapeutic proteins, offering a direct approach to correcting genetic defects.
- Potential to treat a wide range of rare genetic disorders and chronic diseases.
- Ongoing advancements in delivery mechanisms for targeted gene editing and protein replacement.
- Significant R&D investment from major pharmaceutical companies in mRNA-based gene therapies.
- Key Drivers:
Leading Region: North America, particularly the United States, is a dominant region.
- Key Drivers:
- Robust R&D ecosystem and significant venture capital funding for biotechnology.
- Presence of leading mRNA technology developers and manufacturers.
- Favorable regulatory environment that has historically supported rapid drug approvals.
- High healthcare expenditure and strong demand for advanced medical treatments.
- Key Drivers:
The market is projected to see the infectious diseases segment contributing an estimated $18,000 Million to $23,000 Million in 2025, with a projected CAGR of 12% to 17%. Gene therapy applications are expected to grow at a significantly higher rate, with an estimated CAGR of 25% to 30% from 2025 to 2033, indicating its future transformative impact.
mRNA Vaccines Therapeutics Market Product Innovations
Product innovations in the mRNA Vaccines Therapeutics Market are at the forefront of medical advancement. Companies are developing novel mRNA constructs for enhanced protein expression and immunogenicity, coupled with sophisticated lipid nanoparticle (LNP) delivery systems that offer improved targeting and reduced off-target effects. Innovations are expanding beyond infectious disease vaccines to encompass therapeutic applications for cancer, rare genetic disorders, and autoimmune diseases. For instance, self-amplifying mRNA vaccines are demonstrating enhanced potency, requiring lower doses and potentially broadening their applicability. Furthermore, the development of mRNA-based therapies for producing therapeutic proteins within the body, such as antibodies or enzymes, represents a significant leap forward in treating chronic and debilitating conditions. These advancements are continuously improving efficacy, safety profiles, and patient compliance.
Propelling Factors for mRNA Vaccines Therapeutics Market Growth
The mRNA Vaccines Therapeutics Market is propelled by a confluence of powerful factors. Technological Advancements in mRNA synthesis, codon optimization, and delivery systems (particularly lipid nanoparticles) are crucial. The established success of mRNA COVID-19 vaccines has fostered Increased Investor Confidence and Funding, leading to substantial R&D investments. Favorable Regulatory Pathways, streamlined by the pandemic response, continue to encourage innovation. Furthermore, the inherent Versatility of mRNA Platforms allows for rapid development and adaptation to new targets, making it ideal for addressing unmet medical needs in infectious diseases, cancer, and rare genetic disorders. The growing prevalence of these diseases and the increasing demand for novel therapeutic solutions further fuel market expansion, projected to reach approximately $50,000 Million to $70,000 Million by 2033.
Obstacles in the mRNA Vaccines Therapeutics Market Market
Despite its immense promise, the mRNA Vaccines Therapeutics Market faces several obstacles. Manufacturing Scalability and Cost remain significant challenges, particularly for niche therapeutic applications requiring high purity and complex logistics. Stringent Regulatory Hurdles for novel mRNA therapeutics, especially outside of vaccines, require extensive clinical trials and data for approval. Cold Chain Logistics for mRNA products necessitate specialized storage and transportation, adding complexity and cost. Furthermore, Public Perception and Vaccine Hesitancy, fueled by misinformation, can impact adoption rates for certain applications. Intellectual Property Disputes among key players in the rapidly evolving mRNA technology space also present potential barriers to widespread development and commercialization.
Future Opportunities in mRNA Vaccines Therapeutics Market
The future opportunities in the mRNA Vaccines Therapeutics Market are vast and transformative. The expansion into Oncology with personalized cancer vaccines and mRNA-encoded therapeutic proteins holds immense potential. Rare Genetic Diseases represent a significant frontier, with mRNA offering a viable approach to protein replacement therapy. The development of Next-Generation Vaccines against a broader spectrum of infectious agents, including influenza, RSV, and HIV, is a key opportunity. Furthermore, advancements in Combination Therapies, integrating mRNA with other treatment modalities, are expected to unlock new therapeutic paradigms. Exploring novel delivery mechanisms and expanding manufacturing capabilities will also be critical for realizing these future opportunities, driving market growth to an estimated $80,000 Million to $100,000 Million by 2033.
Major Players in the mRNA Vaccines Therapeutics Market Ecosystem
- Daiichi Sankyo
- AstraZeneca
- Sino Biopharmaceutical Limited (pHion Therapeutics Ltd)
- Arcturus Therapeutics Inc
- AIM Vaccine
- GlaxoSmithKline
- Ethris GmbH
- BioNTech SE
- Moderna Inc
- CureVac
- Pfizer Inc
Key Developments in mRNA Vaccines Therapeutics Market Industry
- November 2022: Health Canada authorized the use of the Moderna Spikevax 50 mcg BA.4/5 bivalent COVID-19 vaccine as a booster dose in individuals aged 18 years and older. This development underscores the ongoing adaptation of mRNA vaccines to evolving viral strains and the continuous efforts to enhance population immunity. Health Canada previously authorized similar bivalent booster doses containing Omicron BA.1 or BA.4/5 variants from Moderna (50 mcg) and Pfizer-BioNTech (30 mcg) in September and October of 2022, respectively, highlighting a rapid and responsive regulatory environment for updated vaccines.
- October 2022: Moderna Inc. reported that it had received emergency use authorization (EUA) from the United States Food and Drug Administration (FDA) for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, in children and adolescents aged 6 to 17 years. This milestone signifies the expanding application of mRNA technology to younger age groups, further solidifying its role in pediatric healthcare and public health initiatives.
Strategic mRNA Vaccines Therapeutics Market Market Forecast
The strategic forecast for the mRNA Vaccines Therapeutics Market is exceptionally promising, driven by continuous innovation and expanding applications. The market is poised for sustained growth, fueled by the increasing adoption of mRNA technology beyond infectious diseases into critical areas like oncology, rare genetic disorders, and autoimmune diseases. Significant investments in R&D, coupled with favorable regulatory environments, are expected to accelerate the development and approval of novel mRNA-based therapeutics. The versatility and speed of mRNA platform technology position it as a cornerstone for future medical breakthroughs, offering personalized and highly effective treatment options. Projections indicate a robust market trajectory, with the sector expected to achieve significant market penetration and contribute substantially to global healthcare advancements.
mRNA Vaccines Therapeutics Market Segmentation
-
1. Vaccine Type
- 1.1. Self-amplifying mRNA-based Vaccines
- 1.2. Conventional Non-amplifying mRNA-based Vaccines
-
2. Application
- 2.1. Cancer
- 2.2. Infectious Diseases
- 2.3. Autoimmune Diseases
- 2.4. Other Applications
-
3. Treatment Type
- 3.1. Monoclonal Antibody
- 3.2. Gene Therapy
- 3.3. Cell Therapy
- 3.4. Other Treatment Types
-
4. End User
- 4.1. Research Laboratories and Organizations
- 4.2. Hospitals and Clinics
- 4.3. Other End Users
mRNA Vaccines Therapeutics Market Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. Europe
- 2.1. Germany
- 2.2. United Kingdom
- 2.3. France
- 2.4. Italy
- 2.5. Spain
- 2.6. Rest of Europe
-
3. Asia Pacific
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
-
4. Middle East and Africa
- 4.1. GCC
- 4.2. South Africa
- 4.3. Rest of Middle East and Africa
-
5. South America
- 5.1. Brazil
- 5.2. Argentina
- 5.3. Rest of South America
mRNA Vaccines Therapeutics Market Regional Market Share
Geographic Coverage of mRNA Vaccines Therapeutics Market
mRNA Vaccines Therapeutics Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 16.80% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Soaring Demand for New Vaccines and Therapeutics; Rising Chronic and Infectious Diseases; Increasing R&D Investments by the Government and Market Players
- 3.3. Market Restrains
- 3.3.1. Strict Legal Requirements and Frameworks; High Price Associated with mRNA-based Vaccines and Therapeutics
- 3.4. Market Trends
- 3.4.1. Infectious Disease Segment is Expected to Occupy a Significant Share in the mRNA Vaccines and Therapeutics Market over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global mRNA Vaccines Therapeutics Market Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 5.1.1. Self-amplifying mRNA-based Vaccines
- 5.1.2. Conventional Non-amplifying mRNA-based Vaccines
- 5.2. Market Analysis, Insights and Forecast - by Application
- 5.2.1. Cancer
- 5.2.2. Infectious Diseases
- 5.2.3. Autoimmune Diseases
- 5.2.4. Other Applications
- 5.3. Market Analysis, Insights and Forecast - by Treatment Type
- 5.3.1. Monoclonal Antibody
- 5.3.2. Gene Therapy
- 5.3.3. Cell Therapy
- 5.3.4. Other Treatment Types
- 5.4. Market Analysis, Insights and Forecast - by End User
- 5.4.1. Research Laboratories and Organizations
- 5.4.2. Hospitals and Clinics
- 5.4.3. Other End Users
- 5.5. Market Analysis, Insights and Forecast - by Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Middle East and Africa
- 5.5.5. South America
- 5.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 6. North America mRNA Vaccines Therapeutics Market Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 6.1.1. Self-amplifying mRNA-based Vaccines
- 6.1.2. Conventional Non-amplifying mRNA-based Vaccines
- 6.2. Market Analysis, Insights and Forecast - by Application
- 6.2.1. Cancer
- 6.2.2. Infectious Diseases
- 6.2.3. Autoimmune Diseases
- 6.2.4. Other Applications
- 6.3. Market Analysis, Insights and Forecast - by Treatment Type
- 6.3.1. Monoclonal Antibody
- 6.3.2. Gene Therapy
- 6.3.3. Cell Therapy
- 6.3.4. Other Treatment Types
- 6.4. Market Analysis, Insights and Forecast - by End User
- 6.4.1. Research Laboratories and Organizations
- 6.4.2. Hospitals and Clinics
- 6.4.3. Other End Users
- 6.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 7. Europe mRNA Vaccines Therapeutics Market Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 7.1.1. Self-amplifying mRNA-based Vaccines
- 7.1.2. Conventional Non-amplifying mRNA-based Vaccines
- 7.2. Market Analysis, Insights and Forecast - by Application
- 7.2.1. Cancer
- 7.2.2. Infectious Diseases
- 7.2.3. Autoimmune Diseases
- 7.2.4. Other Applications
- 7.3. Market Analysis, Insights and Forecast - by Treatment Type
- 7.3.1. Monoclonal Antibody
- 7.3.2. Gene Therapy
- 7.3.3. Cell Therapy
- 7.3.4. Other Treatment Types
- 7.4. Market Analysis, Insights and Forecast - by End User
- 7.4.1. Research Laboratories and Organizations
- 7.4.2. Hospitals and Clinics
- 7.4.3. Other End Users
- 7.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 8. Asia Pacific mRNA Vaccines Therapeutics Market Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 8.1.1. Self-amplifying mRNA-based Vaccines
- 8.1.2. Conventional Non-amplifying mRNA-based Vaccines
- 8.2. Market Analysis, Insights and Forecast - by Application
- 8.2.1. Cancer
- 8.2.2. Infectious Diseases
- 8.2.3. Autoimmune Diseases
- 8.2.4. Other Applications
- 8.3. Market Analysis, Insights and Forecast - by Treatment Type
- 8.3.1. Monoclonal Antibody
- 8.3.2. Gene Therapy
- 8.3.3. Cell Therapy
- 8.3.4. Other Treatment Types
- 8.4. Market Analysis, Insights and Forecast - by End User
- 8.4.1. Research Laboratories and Organizations
- 8.4.2. Hospitals and Clinics
- 8.4.3. Other End Users
- 8.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 9. Middle East and Africa mRNA Vaccines Therapeutics Market Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 9.1.1. Self-amplifying mRNA-based Vaccines
- 9.1.2. Conventional Non-amplifying mRNA-based Vaccines
- 9.2. Market Analysis, Insights and Forecast - by Application
- 9.2.1. Cancer
- 9.2.2. Infectious Diseases
- 9.2.3. Autoimmune Diseases
- 9.2.4. Other Applications
- 9.3. Market Analysis, Insights and Forecast - by Treatment Type
- 9.3.1. Monoclonal Antibody
- 9.3.2. Gene Therapy
- 9.3.3. Cell Therapy
- 9.3.4. Other Treatment Types
- 9.4. Market Analysis, Insights and Forecast - by End User
- 9.4.1. Research Laboratories and Organizations
- 9.4.2. Hospitals and Clinics
- 9.4.3. Other End Users
- 9.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 10. South America mRNA Vaccines Therapeutics Market Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 10.1.1. Self-amplifying mRNA-based Vaccines
- 10.1.2. Conventional Non-amplifying mRNA-based Vaccines
- 10.2. Market Analysis, Insights and Forecast - by Application
- 10.2.1. Cancer
- 10.2.2. Infectious Diseases
- 10.2.3. Autoimmune Diseases
- 10.2.4. Other Applications
- 10.3. Market Analysis, Insights and Forecast - by Treatment Type
- 10.3.1. Monoclonal Antibody
- 10.3.2. Gene Therapy
- 10.3.3. Cell Therapy
- 10.3.4. Other Treatment Types
- 10.4. Market Analysis, Insights and Forecast - by End User
- 10.4.1. Research Laboratories and Organizations
- 10.4.2. Hospitals and Clinics
- 10.4.3. Other End Users
- 10.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis 2025
- 11.2. Company Profiles
- 11.2.1 Daiichi Sankyo
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 AstraZeneca
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 Sino Biopharmaceutical Limited (pHion Therapeutics Ltd)
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Arcturus Therapeutics Inc
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 AIM Vaccine
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 GlaxoSmithKline
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 Ethris GmbH
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 BioNTech SE
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 Moderna Inc
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.10 CureVac
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Financials (Based on Availability)
- 11.2.11 Pfizer Inc
- 11.2.11.1. Overview
- 11.2.11.2. Products
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Financials (Based on Availability)
- 11.2.1 Daiichi Sankyo
List of Figures
- Figure 1: Global mRNA Vaccines Therapeutics Market Revenue Breakdown (Million, %) by Region 2025 & 2033
- Figure 2: Global mRNA Vaccines Therapeutics Market Volume Breakdown (K Unit, %) by Region 2025 & 2033
- Figure 3: North America mRNA Vaccines Therapeutics Market Revenue (Million), by Vaccine Type 2025 & 2033
- Figure 4: North America mRNA Vaccines Therapeutics Market Volume (K Unit), by Vaccine Type 2025 & 2033
- Figure 5: North America mRNA Vaccines Therapeutics Market Revenue Share (%), by Vaccine Type 2025 & 2033
- Figure 6: North America mRNA Vaccines Therapeutics Market Volume Share (%), by Vaccine Type 2025 & 2033
- Figure 7: North America mRNA Vaccines Therapeutics Market Revenue (Million), by Application 2025 & 2033
- Figure 8: North America mRNA Vaccines Therapeutics Market Volume (K Unit), by Application 2025 & 2033
- Figure 9: North America mRNA Vaccines Therapeutics Market Revenue Share (%), by Application 2025 & 2033
- Figure 10: North America mRNA Vaccines Therapeutics Market Volume Share (%), by Application 2025 & 2033
- Figure 11: North America mRNA Vaccines Therapeutics Market Revenue (Million), by Treatment Type 2025 & 2033
- Figure 12: North America mRNA Vaccines Therapeutics Market Volume (K Unit), by Treatment Type 2025 & 2033
- Figure 13: North America mRNA Vaccines Therapeutics Market Revenue Share (%), by Treatment Type 2025 & 2033
- Figure 14: North America mRNA Vaccines Therapeutics Market Volume Share (%), by Treatment Type 2025 & 2033
- Figure 15: North America mRNA Vaccines Therapeutics Market Revenue (Million), by End User 2025 & 2033
- Figure 16: North America mRNA Vaccines Therapeutics Market Volume (K Unit), by End User 2025 & 2033
- Figure 17: North America mRNA Vaccines Therapeutics Market Revenue Share (%), by End User 2025 & 2033
- Figure 18: North America mRNA Vaccines Therapeutics Market Volume Share (%), by End User 2025 & 2033
- Figure 19: North America mRNA Vaccines Therapeutics Market Revenue (Million), by Country 2025 & 2033
- Figure 20: North America mRNA Vaccines Therapeutics Market Volume (K Unit), by Country 2025 & 2033
- Figure 21: North America mRNA Vaccines Therapeutics Market Revenue Share (%), by Country 2025 & 2033
- Figure 22: North America mRNA Vaccines Therapeutics Market Volume Share (%), by Country 2025 & 2033
- Figure 23: Europe mRNA Vaccines Therapeutics Market Revenue (Million), by Vaccine Type 2025 & 2033
- Figure 24: Europe mRNA Vaccines Therapeutics Market Volume (K Unit), by Vaccine Type 2025 & 2033
- Figure 25: Europe mRNA Vaccines Therapeutics Market Revenue Share (%), by Vaccine Type 2025 & 2033
- Figure 26: Europe mRNA Vaccines Therapeutics Market Volume Share (%), by Vaccine Type 2025 & 2033
- Figure 27: Europe mRNA Vaccines Therapeutics Market Revenue (Million), by Application 2025 & 2033
- Figure 28: Europe mRNA Vaccines Therapeutics Market Volume (K Unit), by Application 2025 & 2033
- Figure 29: Europe mRNA Vaccines Therapeutics Market Revenue Share (%), by Application 2025 & 2033
- Figure 30: Europe mRNA Vaccines Therapeutics Market Volume Share (%), by Application 2025 & 2033
- Figure 31: Europe mRNA Vaccines Therapeutics Market Revenue (Million), by Treatment Type 2025 & 2033
- Figure 32: Europe mRNA Vaccines Therapeutics Market Volume (K Unit), by Treatment Type 2025 & 2033
- Figure 33: Europe mRNA Vaccines Therapeutics Market Revenue Share (%), by Treatment Type 2025 & 2033
- Figure 34: Europe mRNA Vaccines Therapeutics Market Volume Share (%), by Treatment Type 2025 & 2033
- Figure 35: Europe mRNA Vaccines Therapeutics Market Revenue (Million), by End User 2025 & 2033
- Figure 36: Europe mRNA Vaccines Therapeutics Market Volume (K Unit), by End User 2025 & 2033
- Figure 37: Europe mRNA Vaccines Therapeutics Market Revenue Share (%), by End User 2025 & 2033
- Figure 38: Europe mRNA Vaccines Therapeutics Market Volume Share (%), by End User 2025 & 2033
- Figure 39: Europe mRNA Vaccines Therapeutics Market Revenue (Million), by Country 2025 & 2033
- Figure 40: Europe mRNA Vaccines Therapeutics Market Volume (K Unit), by Country 2025 & 2033
- Figure 41: Europe mRNA Vaccines Therapeutics Market Revenue Share (%), by Country 2025 & 2033
- Figure 42: Europe mRNA Vaccines Therapeutics Market Volume Share (%), by Country 2025 & 2033
- Figure 43: Asia Pacific mRNA Vaccines Therapeutics Market Revenue (Million), by Vaccine Type 2025 & 2033
- Figure 44: Asia Pacific mRNA Vaccines Therapeutics Market Volume (K Unit), by Vaccine Type 2025 & 2033
- Figure 45: Asia Pacific mRNA Vaccines Therapeutics Market Revenue Share (%), by Vaccine Type 2025 & 2033
- Figure 46: Asia Pacific mRNA Vaccines Therapeutics Market Volume Share (%), by Vaccine Type 2025 & 2033
- Figure 47: Asia Pacific mRNA Vaccines Therapeutics Market Revenue (Million), by Application 2025 & 2033
- Figure 48: Asia Pacific mRNA Vaccines Therapeutics Market Volume (K Unit), by Application 2025 & 2033
- Figure 49: Asia Pacific mRNA Vaccines Therapeutics Market Revenue Share (%), by Application 2025 & 2033
- Figure 50: Asia Pacific mRNA Vaccines Therapeutics Market Volume Share (%), by Application 2025 & 2033
- Figure 51: Asia Pacific mRNA Vaccines Therapeutics Market Revenue (Million), by Treatment Type 2025 & 2033
- Figure 52: Asia Pacific mRNA Vaccines Therapeutics Market Volume (K Unit), by Treatment Type 2025 & 2033
- Figure 53: Asia Pacific mRNA Vaccines Therapeutics Market Revenue Share (%), by Treatment Type 2025 & 2033
- Figure 54: Asia Pacific mRNA Vaccines Therapeutics Market Volume Share (%), by Treatment Type 2025 & 2033
- Figure 55: Asia Pacific mRNA Vaccines Therapeutics Market Revenue (Million), by End User 2025 & 2033
- Figure 56: Asia Pacific mRNA Vaccines Therapeutics Market Volume (K Unit), by End User 2025 & 2033
- Figure 57: Asia Pacific mRNA Vaccines Therapeutics Market Revenue Share (%), by End User 2025 & 2033
- Figure 58: Asia Pacific mRNA Vaccines Therapeutics Market Volume Share (%), by End User 2025 & 2033
- Figure 59: Asia Pacific mRNA Vaccines Therapeutics Market Revenue (Million), by Country 2025 & 2033
- Figure 60: Asia Pacific mRNA Vaccines Therapeutics Market Volume (K Unit), by Country 2025 & 2033
- Figure 61: Asia Pacific mRNA Vaccines Therapeutics Market Revenue Share (%), by Country 2025 & 2033
- Figure 62: Asia Pacific mRNA Vaccines Therapeutics Market Volume Share (%), by Country 2025 & 2033
- Figure 63: Middle East and Africa mRNA Vaccines Therapeutics Market Revenue (Million), by Vaccine Type 2025 & 2033
- Figure 64: Middle East and Africa mRNA Vaccines Therapeutics Market Volume (K Unit), by Vaccine Type 2025 & 2033
- Figure 65: Middle East and Africa mRNA Vaccines Therapeutics Market Revenue Share (%), by Vaccine Type 2025 & 2033
- Figure 66: Middle East and Africa mRNA Vaccines Therapeutics Market Volume Share (%), by Vaccine Type 2025 & 2033
- Figure 67: Middle East and Africa mRNA Vaccines Therapeutics Market Revenue (Million), by Application 2025 & 2033
- Figure 68: Middle East and Africa mRNA Vaccines Therapeutics Market Volume (K Unit), by Application 2025 & 2033
- Figure 69: Middle East and Africa mRNA Vaccines Therapeutics Market Revenue Share (%), by Application 2025 & 2033
- Figure 70: Middle East and Africa mRNA Vaccines Therapeutics Market Volume Share (%), by Application 2025 & 2033
- Figure 71: Middle East and Africa mRNA Vaccines Therapeutics Market Revenue (Million), by Treatment Type 2025 & 2033
- Figure 72: Middle East and Africa mRNA Vaccines Therapeutics Market Volume (K Unit), by Treatment Type 2025 & 2033
- Figure 73: Middle East and Africa mRNA Vaccines Therapeutics Market Revenue Share (%), by Treatment Type 2025 & 2033
- Figure 74: Middle East and Africa mRNA Vaccines Therapeutics Market Volume Share (%), by Treatment Type 2025 & 2033
- Figure 75: Middle East and Africa mRNA Vaccines Therapeutics Market Revenue (Million), by End User 2025 & 2033
- Figure 76: Middle East and Africa mRNA Vaccines Therapeutics Market Volume (K Unit), by End User 2025 & 2033
- Figure 77: Middle East and Africa mRNA Vaccines Therapeutics Market Revenue Share (%), by End User 2025 & 2033
- Figure 78: Middle East and Africa mRNA Vaccines Therapeutics Market Volume Share (%), by End User 2025 & 2033
- Figure 79: Middle East and Africa mRNA Vaccines Therapeutics Market Revenue (Million), by Country 2025 & 2033
- Figure 80: Middle East and Africa mRNA Vaccines Therapeutics Market Volume (K Unit), by Country 2025 & 2033
- Figure 81: Middle East and Africa mRNA Vaccines Therapeutics Market Revenue Share (%), by Country 2025 & 2033
- Figure 82: Middle East and Africa mRNA Vaccines Therapeutics Market Volume Share (%), by Country 2025 & 2033
- Figure 83: South America mRNA Vaccines Therapeutics Market Revenue (Million), by Vaccine Type 2025 & 2033
- Figure 84: South America mRNA Vaccines Therapeutics Market Volume (K Unit), by Vaccine Type 2025 & 2033
- Figure 85: South America mRNA Vaccines Therapeutics Market Revenue Share (%), by Vaccine Type 2025 & 2033
- Figure 86: South America mRNA Vaccines Therapeutics Market Volume Share (%), by Vaccine Type 2025 & 2033
- Figure 87: South America mRNA Vaccines Therapeutics Market Revenue (Million), by Application 2025 & 2033
- Figure 88: South America mRNA Vaccines Therapeutics Market Volume (K Unit), by Application 2025 & 2033
- Figure 89: South America mRNA Vaccines Therapeutics Market Revenue Share (%), by Application 2025 & 2033
- Figure 90: South America mRNA Vaccines Therapeutics Market Volume Share (%), by Application 2025 & 2033
- Figure 91: South America mRNA Vaccines Therapeutics Market Revenue (Million), by Treatment Type 2025 & 2033
- Figure 92: South America mRNA Vaccines Therapeutics Market Volume (K Unit), by Treatment Type 2025 & 2033
- Figure 93: South America mRNA Vaccines Therapeutics Market Revenue Share (%), by Treatment Type 2025 & 2033
- Figure 94: South America mRNA Vaccines Therapeutics Market Volume Share (%), by Treatment Type 2025 & 2033
- Figure 95: South America mRNA Vaccines Therapeutics Market Revenue (Million), by End User 2025 & 2033
- Figure 96: South America mRNA Vaccines Therapeutics Market Volume (K Unit), by End User 2025 & 2033
- Figure 97: South America mRNA Vaccines Therapeutics Market Revenue Share (%), by End User 2025 & 2033
- Figure 98: South America mRNA Vaccines Therapeutics Market Volume Share (%), by End User 2025 & 2033
- Figure 99: South America mRNA Vaccines Therapeutics Market Revenue (Million), by Country 2025 & 2033
- Figure 100: South America mRNA Vaccines Therapeutics Market Volume (K Unit), by Country 2025 & 2033
- Figure 101: South America mRNA Vaccines Therapeutics Market Revenue Share (%), by Country 2025 & 2033
- Figure 102: South America mRNA Vaccines Therapeutics Market Volume Share (%), by Country 2025 & 2033
List of Tables
- Table 1: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Vaccine Type 2020 & 2033
- Table 2: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Vaccine Type 2020 & 2033
- Table 3: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Application 2020 & 2033
- Table 4: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Application 2020 & 2033
- Table 5: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Treatment Type 2020 & 2033
- Table 6: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Treatment Type 2020 & 2033
- Table 7: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by End User 2020 & 2033
- Table 8: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by End User 2020 & 2033
- Table 9: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Region 2020 & 2033
- Table 10: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Region 2020 & 2033
- Table 11: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Vaccine Type 2020 & 2033
- Table 12: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Vaccine Type 2020 & 2033
- Table 13: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Application 2020 & 2033
- Table 14: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Application 2020 & 2033
- Table 15: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Treatment Type 2020 & 2033
- Table 16: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Treatment Type 2020 & 2033
- Table 17: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by End User 2020 & 2033
- Table 18: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by End User 2020 & 2033
- Table 19: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Country 2020 & 2033
- Table 20: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 21: United States mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 22: United States mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 23: Canada mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 24: Canada mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 25: Mexico mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 26: Mexico mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 27: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Vaccine Type 2020 & 2033
- Table 28: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Vaccine Type 2020 & 2033
- Table 29: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Application 2020 & 2033
- Table 30: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Application 2020 & 2033
- Table 31: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Treatment Type 2020 & 2033
- Table 32: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Treatment Type 2020 & 2033
- Table 33: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by End User 2020 & 2033
- Table 34: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by End User 2020 & 2033
- Table 35: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Country 2020 & 2033
- Table 36: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 37: Germany mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 38: Germany mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 39: United Kingdom mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 40: United Kingdom mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 41: France mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 42: France mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 43: Italy mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 44: Italy mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 45: Spain mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 46: Spain mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 47: Rest of Europe mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 48: Rest of Europe mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 49: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Vaccine Type 2020 & 2033
- Table 50: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Vaccine Type 2020 & 2033
- Table 51: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Application 2020 & 2033
- Table 52: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Application 2020 & 2033
- Table 53: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Treatment Type 2020 & 2033
- Table 54: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Treatment Type 2020 & 2033
- Table 55: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by End User 2020 & 2033
- Table 56: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by End User 2020 & 2033
- Table 57: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Country 2020 & 2033
- Table 58: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 59: China mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 60: China mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 61: Japan mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 62: Japan mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 63: India mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 64: India mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 65: Australia mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 66: Australia mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 67: South Korea mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 68: South Korea mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 69: Rest of Asia Pacific mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 70: Rest of Asia Pacific mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 71: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Vaccine Type 2020 & 2033
- Table 72: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Vaccine Type 2020 & 2033
- Table 73: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Application 2020 & 2033
- Table 74: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Application 2020 & 2033
- Table 75: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Treatment Type 2020 & 2033
- Table 76: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Treatment Type 2020 & 2033
- Table 77: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by End User 2020 & 2033
- Table 78: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by End User 2020 & 2033
- Table 79: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Country 2020 & 2033
- Table 80: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 81: GCC mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 82: GCC mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 83: South Africa mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 84: South Africa mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 85: Rest of Middle East and Africa mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 86: Rest of Middle East and Africa mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 87: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Vaccine Type 2020 & 2033
- Table 88: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Vaccine Type 2020 & 2033
- Table 89: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Application 2020 & 2033
- Table 90: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Application 2020 & 2033
- Table 91: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Treatment Type 2020 & 2033
- Table 92: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Treatment Type 2020 & 2033
- Table 93: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by End User 2020 & 2033
- Table 94: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by End User 2020 & 2033
- Table 95: Global mRNA Vaccines Therapeutics Market Revenue Million Forecast, by Country 2020 & 2033
- Table 96: Global mRNA Vaccines Therapeutics Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 97: Brazil mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 98: Brazil mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 99: Argentina mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 100: Argentina mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 101: Rest of South America mRNA Vaccines Therapeutics Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 102: Rest of South America mRNA Vaccines Therapeutics Market Volume (K Unit) Forecast, by Application 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the mRNA Vaccines Therapeutics Market?
The projected CAGR is approximately 16.80%.
2. Which companies are prominent players in the mRNA Vaccines Therapeutics Market?
Key companies in the market include Daiichi Sankyo, AstraZeneca, Sino Biopharmaceutical Limited (pHion Therapeutics Ltd), Arcturus Therapeutics Inc, AIM Vaccine, GlaxoSmithKline, Ethris GmbH, BioNTech SE, Moderna Inc, CureVac, Pfizer Inc.
3. What are the main segments of the mRNA Vaccines Therapeutics Market?
The market segments include Vaccine Type, Application, Treatment Type, End User.
4. Can you provide details about the market size?
The market size is estimated to be USD 54.70 Million as of 2022.
5. What are some drivers contributing to market growth?
Soaring Demand for New Vaccines and Therapeutics; Rising Chronic and Infectious Diseases; Increasing R&D Investments by the Government and Market Players.
6. What are the notable trends driving market growth?
Infectious Disease Segment is Expected to Occupy a Significant Share in the mRNA Vaccines and Therapeutics Market over the Forecast Period.
7. Are there any restraints impacting market growth?
Strict Legal Requirements and Frameworks; High Price Associated with mRNA-based Vaccines and Therapeutics.
8. Can you provide examples of recent developments in the market?
November 2022: Health Canada authorized the use of the Moderna Spikevax 50 mcg BA.4/5 bivalent COVID-19 vaccine as a booster dose in individuals aged 18 years and older. Health Canada previously authorized similar bivalent booster doses containing Omicron BA.1 or BA.4/5 variants from Moderna (50 mcg) and Pfizer-BioNTech (30 mcg) in September and October of 2022, respectively.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million and volume, measured in K Unit.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "mRNA Vaccines Therapeutics Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the mRNA Vaccines Therapeutics Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the mRNA Vaccines Therapeutics Market?
To stay informed about further developments, trends, and reports in the mRNA Vaccines Therapeutics Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence